Literature DB >> 10714098

Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia.

Y H Lee1, S J Choi, J D Ji, J J Shim, K H Kang, H D Cho, H K Kim, G G Song.   

Abstract

A case of dermatomyositis presented as bronchiolitis obliterans organizing pneumonia has been rarely reported. We describe a 46-year-old female patient with dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. She was treated with prednisolone and azathioprine. Over a 2-year follow-up she has had no elevation of creatine kinase. The patient remains asymptomatic and has no medication for dermatomyositis and bronchiolitis obliterans organizing pneumonia two years after initial treatment. It has been suggested that the prognosis of dermatomyositis without creatine kinase elevation may be poor. Because the prognosis of bronchiolitis obliterans organizing pneumonia is generally believed to be good, we tentatively suggest that the normal value of creatine kinase in dermatomyositis does not always seem to herald a poor prognosis, an associated malignancy or severe interstitial lung disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714098      PMCID: PMC4531735          DOI: 10.3904/kjim.2000.15.1.85

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  9 in total

1.  Normal creatine kinase activity in idiopathic inflammatory myopathy: does it have prognostic implications?

Authors:  J Fernandez-Sola; J C Pou; J M Junyent; A Urbano-Manquez
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

2.  Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis.

Authors:  F Fata; R Rathore; C Schiff; B C Herzlich
Journal:  South Med J       Date:  1997-02       Impact factor: 0.954

3.  Absence of elevated creatine kinase in dermatomyositis does not exclude malignancy.

Authors:  G La Montagna; C Manzo; E Califano; R Tirri
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

4.  Dermatomyositis without creatine kinase elevation.

Authors:  D Nicholls
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

5.  Dermatomyositis without creatine kinase elevation. A poor prognostic sign.

Authors:  E J Fudman; T J Schnitzer
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

Review 6.  Adult idiopathic polymyositis without elevation of creatine kinase. Case report and review of the literature.

Authors:  J T Gran; G Myklebust; S Johansen
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

Review 7.  Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature.

Authors:  R L Euwer; R D Sontheimer
Journal:  J Am Acad Dermatol       Date:  1991-06       Impact factor: 11.527

8.  Case Report: amyopathic dermatomyositis associated with transformed malignant lymphoma.

Authors:  Y Osman; M Narita; K Kishi; H Fujiwara; T Fukuda; T Koike; A Shibata
Journal:  Am J Med Sci       Date:  1996-05       Impact factor: 2.378

9.  Rapidly progressive bronchiolitis obliterans with organizing pneumonia.

Authors:  A J Cohen; T E King; G P Downey
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

  9 in total
  2 in total

Review 1.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study.

Authors:  Javier Loaiza-Félix; Mariana Moreno-Ramírez; F Luis Pérez-García; Valentín Jiménez-Rojas; Fausto Sánchez-Muñoz; M Luis Amezcua-Guerra
Journal:  Rheumatol Int       Date:  2017-05-23       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.